Precision Biosciences. has filed a patent for engineered meganucleases targeting a specific sequence in the Hepatitis B virus genome. These nucleases show improved characteristics compared to previous versions and can be used in pharmaceutical compositions for treating HBV infections or hepatocellular carcinoma. GlobalData’s report on Precision Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Precision Biosciences, Gene splicing using nucleases was a key innovation area identified from patents. Precision Biosciences's grant share as of January 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.
Engineered meganuclease for treating hepatitis b virus infections
See Also:
A recently filed patent (Publication Number: US20240035011A1) discloses an engineered meganuclease designed to target and cleave a specific recognition sequence within the Hepatitis B virus genome. This engineered meganuclease consists of two subunits, with the first subunit binding to one half of the recognition sequence and containing a hypervariable region with specific amino acid residues. The second subunit binds to the other half of the recognition sequence and also contains a hypervariable region with defined amino acid residues. The patent claims cover various aspects of the engineered meganuclease, including the specific amino acid sequences, characteristics, and applications in treating Hepatitis B virus or hepatocellular carcinoma caused by the virus.
Furthermore, the patent application extends to polynucleotides encoding the engineered meganuclease, recombinant DNA constructs incorporating the nucleic acid sequences, viral vectors containing the engineered meganuclease, and pharmaceutical compositions for treating Hepatitis B virus infections. The disclosed method involves delivering the engineered meganuclease to target cells to reduce or eliminate Hepatitis B virus infection and proliferation. The patent also includes claims for using the engineered meganuclease in medicine and specifically for treating Hepatitis B virus infections or associated hepatocellular carcinoma. Overall, the patent outlines a comprehensive approach to utilizing the engineered meganuclease for targeted therapy against Hepatitis B virus, showcasing potential advancements in the field of genetic engineering for antiviral treatments.
To know more about GlobalData’s detailed insights on Precision Biosciences, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
